<DOC>
	<DOC>NCT00092885</DOC>
	<brief_summary>The purpose of this study is to determine the effect of an approved medication on the symptoms of seasonal allergic rhinitis (a seasonal variety of inflammation of the mucous membrane of the nose) in patients who are experiencing symptoms of seasonal allergic rhinitis and asthma.</brief_summary>
	<brief_title>An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)</brief_title>
	<detailed_description>The duration of treatment is 2 weeks.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Nonsmoker A 2year documented history of seasonal allergic rhinitis A 1year documented history of chronic asthma Positive allergy testing Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>